Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity
Paola Alberti,Davide P Bernasconi,David R Cornblath,Ingemar S J Merkies,Susanna B Park,Roser Velasco,Jordi Bruna,Dimitri Psimaras,Susanne Koeppen,Andrea Pace,Susan G Dorsey,Andreas A Argyriou,Haralabos P Kalofonos,Chiara Briani,Angelo Schenone,Catharina G Faber,Anna Mazzeo,Wolfgang Grisold,MariaGrazia Valsecchi,Guido Cavaletti,CI-PeriNomS group,Marina Elena Cazzaniga,Raffaella Longarini,Alessandro Guidi,Tjeerd J Postma,David Goldstein,Damien Ricard,Camille Tafani,DuBose Brooks,Cynthia L Renn,Edvina Galiè,Marta Campagnolo,Francesca Castellani,Marina Grandis,Roy I Lalisang,Luca Gentile,Massimo Russo,Antonio Toscano
DOI: https://doi.org/10.1212/WNL.0000000000012300
IF: 9.9
2021-08-17
Neurology
Abstract:Background and objective: There is no agreement on the gold standard for detection and grading of chemotherapy-induced peripheral neurotoxicity (CIPN) in clinical trials. The objective is to perform an observational prospective study to assess and compare patient-based and physician-based methods for detection and grading of CIPN. Methods: Consecutive patients, aged 18 years or older, candidates for neurotoxic chemotherapy, were enrolled in the United States, European Union, or Australia. A trained investigator performed physician-based scales (Total Neuropathy Score-clinical [TNSc], used to calculate Total Neuropathy Score-nurse [TNSn]) and supervised the patient-completed questionnaire (Functional Assessment of Cancer Treatment/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-NTX]). Evaluations were performed before and at the end of chemotherapy. On participants without neuropathy at baseline, we assessed the association between TNSc, TNSn, and FACT/GOG-NTX. Considering a previously established minimal clinically important difference (MCID) for FACT/GOG-NTX, we identified participants with and without a clinically important deterioration according to this scale. Then, we calculated the MCID for TNSc and TNSn as the difference in the mean change score of these scales between the 2 groups. Results: Data from 254 participants were available: 180 (71%) had normal neurologic status at baseline. At the end of the study, 88% of participants developed any grade of neuropathy. TNSc, TNSn, and FACT/GOG-NTX showed good responsiveness (standardized mean change from baseline to end of chemotherapy >1 for all scales). On the 153 participants without neuropathy at baseline and treated with a known neurotoxic chemotherapy regimen, we verified a moderate correlation in both TNSc and TNSn scores with FACT/GOG-NTX (Spearman correlation index r = 0.6). On the same sample, considering as clinically important a change in the FACT/GOG-NTX score of at least 3.3 points, the MCID was 3.7 for TNSc and 2.8 for the TNSn. Conclusions: MCID for TNSc and TNSn were calculated and the TNSn can be considered a reliable alternative objective clinical assessment if a more extended neurologic examination is not possible. The FACT/GOG-NTX score can be reduced to 7 items and these items correlate well with the TNSc and TNSn. Classification of evidence: This study provides Class III evidence that a patient-completed questionnaire and nurse-assessed scale correlate with a physician-assessed scale.